<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595399</url>
  </required_header>
  <id_info>
    <org_study_id>R500458</org_study_id>
    <nct_id>NCT01595399</nct_id>
  </id_info>
  <brief_title>Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation</brief_title>
  <official_title>Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare heart rate in infants who receive atropine as a part
      of their medication before intubation to those who do not.

      To be able to find out , we need to divided babies into 2 groups;

      group 1 : receives atropine + sedation + muscle relaxant group 2 : receives water or saline (
      placebo group) + sedation + muscle relaxant

      Then we need to compare heart rate during intubation and duration of intubation between the 2
      groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that premedication for intubation with fentanyl and succinylcholine alone will
      maintain equal stability of heart rate and oxygen saturation without a prolongation of time
      to completion of intubation when compared to a protocol using atropine, fentanyl and
      succinylcholine.

      In order to answer this question we plan to undertake a prospective randomized double blinded
      control trial of use of atropine as an adjunct for elective intubation of infants less than
      46 weeks postmenstrual age.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate less than 80 BPM and oxygen saturation less than 80%</measure>
    <time_frame>5-6 minutes</time_frame>
    <description>Heart rate and transcutaneous oxygen saturation will be monitored continuously during the procedure and data will be recorded at 3 stages;
2 minutes prior to intubation (after atropine or placebo dose)
during intubation
2 minutes after intubation (once ETT secured to face)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate &lt; 100 BPM</measure>
    <time_frame>5-6 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation &lt; 85%</measure>
    <time_frame>5-6 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intubation attempts</measure>
    <time_frame>1-2 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intubation attempts</measure>
    <time_frame>5-6 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest heart rate after premedication</measure>
    <time_frame>5-6 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest oxygen saturation after premedication</measure>
    <time_frame>5-6 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Bradycardia</condition>
  <condition>Hypoxemia</condition>
  <arm_group>
    <arm_group_label>Atropine, fentanyl and succinylcholine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mcg/kg atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, fentanyl and succinylcholine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>an equivalent volume of normal saline to atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atropine</intervention_name>
    <description>Atropine 0.02 mg/kg IV</description>
    <arm_group_label>Atropine, fentanyl and succinylcholine</arm_group_label>
    <other_name>AtroPen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>an equivalent volume of normal saline to atropine IV</description>
    <arm_group_label>placebo, fentanyl and succinylcholine</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any infant (preterm and term) up to 46 weeks corrected age requiring (nonemergent)
             intubation.

          -  IV access is obtained

          -  Informed parental consent

        Exclusion Criteria:

          -  Emergent intubation or need for resuscitation

          -  Congenital cyanotic heart disease

          -  Obvious airway abnormalities

          -  History of myopathy or family history of malignant hyperthermia or known history of
             phosphocholinesterase deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R Narvey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael R Narvey, MD</last_name>
    <phone>2047872720</phone>
    <email>mnarvey@hsc.mb.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jehier Afifi, MD</last_name>
    <phone>9024706944</phone>
    <email>Jehier.afifi@iwk.nshealth.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Narvey, MD</last_name>
      <phone>2047872720</phone>
      <email>mnarvey@hsc.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Michael R Narvey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jehier Afifi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Baier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bradycardia</keyword>
  <keyword>hypoxemia</keyword>
  <keyword>intubation</keyword>
  <keyword>premedication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Succinylcholine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

